Document:

EXHIBIT 10.15

                       LICENSE AND DISTRIBUTION AGREEMENT

         This License and Distribution Agreement (the "Agreement") is entered
into as of this 12th day of December, 2005 (the "Effective Date") between
SAMARITAN PHARMACEUTICALS EUROPE, S.A., with offices 41 Skoufa Street, Athens
--- 10673 Greece, (hereinafter referred to as "SAMARITAN") and THREE RIVERS
PHARMACEUTICALS, LLC, with offices at 312 Commerce Park Drive, Cranberry
Township, Pennsylvania, USA 16066 (herein referred to as "3RP").

                                    RECITALS

         WHEREAS, 3RP desires SAMARITAN to arrange for, or continue in force,
the regulatory approval and distribution of the Product in the Territory; and

         WHEREAS, SAMARITAN is engaged in distributing pharmaceutical products
in the Territory and possesses qualified marketing and distribution systems to
enable it to effectively promote, market and distribute the Product throughout
the Territory.

         NOW, THEREFORE, in consideration of the representations, warranties,
covenants and obligations hereinafter set forth, the parties intending to be
legally bound, mutually agree as follows:

                   ARTICLE 1 - DEFINITIONS AND INTERPRETATION

 1.1     Definitions: Whenever used in this Agreement (including the recitals),
         the words and terms set forth on Schedule "A", annexed hereto, shall
         have the respective meanings ascribed thereto.

 1.2     Headings: The headings of all Articles and Sections hereof are inserted
         for convenience of reference only, are not intended to be full or
         accurate descriptions of the contents hereof and shall not be
         considered part of this Agreement or affect the construction or
         interpretation of this Agreement.

 1.3     No Strict Construction: The language used in this Agreement shall be
         deemed to be the language chosen by the parties hereto to express their
         mutual intent and no rule of strict construction against any party
         shall apply to any term or condition of this Agreement.

 1.4     Governing Law: This Agreement and any question concerning its validity,
         construction or performance, regardless of the forum wherein any such
         issue may be litigated, shall be governed by the laws of the
         Commonwealth of Pennsylvania and the laws of the United States
         applicable therein, without reference to the Commonwealth of
         Pennsylvania's conflicts of law provisions, irrespective of the place
         of execution or the order in which the signatures of the parties are
         affixed, or the place or places of performance.

 1.5     Reference to Laws, etc.: Any references herein to any law, statute,
         regulation, order, rule or guideline of any government, governmental
         body or other Regulatory Authority shall be construed as a reference
         thereto as amended or re-enacted from time to time.

<PAGE>

                        ARTICLE 2 - EXCLUSIVE APPOINTMENT

 2.1     Exclusive Distributor: Subject to the provisions of this Agreement, 3RP
         hereby appoints SAMARITAN as the sole and exclusive distributor of the
         Product in the Territory and SAMARITAN hereby accepts such appointment
         and agrees to act as such distributor upon terms and conditions herein
         provided.

 2.2     Nature of Relationship: The relationship created hereby between
         SAMARITAN and 3RP is solely that of buyer and seller, and licensor and
         licensee, and each is an independent contractor engaged in the
         operation of its own respective business. Neither party shall be
         considered to be an agent of the other for any purpose whatsoever and,
         except as expressly provided herein, neither party has the power or
         authority to act for, represent, or bind the other in any manner. This
         Agreement does not constitute or create (and the parties do not intend
         to create hereby) a joint venture or partnership of any kind between
         the parties, and the rights and obligations of the parties shall be
         only those expressly set forth herein.

 2.3     Territorial and Product Restrictions Applicable to SAMARITAN: During
         the term of this Agreement SAMARITAN shall not, directly or indirectly,
         sell the Product outside of the Territory. In addition, SAMARITAN shall
         not, directly or indirectly, market, sell or distribute a Competing
         Product in the Territory at any time during the term of this Agreement.
         In any and all events, if SAMARITAN receives an order for or an inquiry
         concerning the Product from any potential customer for delivery outside
         of the Territory, SAMARITAN shall promptly refer such order or inquiry,
         or cause such order or inquiry to be referred, to 3RP. 3RP may suspend
         supply of the Product to SAMARITAN during any period of time that
         SAMARITAN is in violation of the covenant made under this Section 2.3.

   2.4   Territorial Restrictions Applicable to 3RP: 3RP agrees that during the
         term of this Agreement it shall not, directly or indirectly, sell the
         Product or a Competing Product in the Territory. If, during the term of
         this Agreement 3RP receives an order for or inquiry concerning the
         Product from a potential customer for delivery in the Territory, 3RP
         shall promptly refer such order or inquiry to SAMARITAN.

             ARTICLE 3 - LICENSE AND TRANSFER OF PRODUCT INFORMATION

 3.1     License of Product Information: 3RP hereby grants to SAMARITAN, for the
         term hereof and all renewals and extensions thereof, and SAMARITAN
         hereby accepts, an exclusive license to use the Product Information (as
         defined in Section 3.2 below) to obtain and maintain the required
         Regulatory Approval in the Territory to enable SAMARITAN to market,
         sell and distribute the Product in the Territory for its approved use.
         SAMARITAN hereby acknowledges and agrees that the license hereby
         granted is a limited license (without right to sublicense) to use such
         Product Information solely for the purpose of acquiring and maintaining
         such Regulatory Approval and distributing the Product in the Territory
         pursuant to and in accordance with the provisions of this Agreement and
         for no other purpose (it being understood and agreed that the Product
         Information shall form part of the Confidential Information of 3RP and
         shall be subject to the provisions of Article 13 hereof).

<PAGE>

3.2      Product Information:

(a)            For purposes of this Agreement the "Product Information" shall be
               comprised of all or such portions of the Product dossier and
               Product information including, without limitation, formulation,
               analytical, cleaning, dissolution and manufacturing and testing
               methodologies and processes, which SAMARITAN reasonably needs,
               and is required by the Regulatory Authority, to obtain and
               maintain the Regulatory Approval. 3RP shall, throughout the term
               of this Agreement, promptly provide to SAMARITAN all relevant
               information which 3RP shall from time to time have available to
               it regarding any changes or additions to the Product Information
               (including, without limitation, sources of raw materials,
               formulae, methods of manufacture, specifications, primary
               packaging components and stability) which is applicable to
               obtaining or maintaining any Regulatory Approval;

(b)            3RP agrees that during the term of this Agreement it will not
               directly or indirectly use (except in fulfilling its
               obligations to SAMARITAN under this Agreement), or license any
               other Person to use, the Product Information in the Territory
               in connection with the Product or a Competing Product.

                            ARTICLE 4 - REGISTRATION

 4.1     Product Registration and Maintenance: SAMARITAN shall at its own cost
         and expense apply for, obtain, maintain and renew all necessary
         registrations, permits and other approvals necessary to obtain
         Regulatory Approval of the Product in the Territory. All necessary
         registrations, permits or other approvals received in connection with
         any Regulatory Approval shall be held under SAMARITAN'S name. SAMARITAN
         acknowledges and agrees that 3RP is the beneficial of the Regulatory
         Approval and upon any termination of the Agreement SAMARITAN shall
         assign cause the transfer of any such registrations, permits or other
         approvals to 3RP or 3RP's designee as provided under Section 11.2
         hereof;

  4.2     Regulatory Compliance:

(a)               3RP shall during the term of this Agreement manufacture the
                  Product under the requirements of the relevant Code of Good
                  Manufacturing Practice of the Territory as in effect at the
                  time of delivery of the Product. Throughout the term of this
                  Agreement SAMARITAN shall notify 3RP of any changes to the
                  Code of Good Manufacturing Practices of the Territory;

(b)               Except with SAMARITAN's prior written approval, such approval
                  not to be unreasonably withheld, 3RP shall not make any
                  alteration or change to the Specifications for the Product if
                  such change would adversely affect Regulatory Approval in the
                  Territory.

<PAGE>

 4.3     Mutual Disclosure of Adverse Effects: SAMARITAN and 3RP each agrees
         that it will inform the other of them of all information that comes
         into its possession or control and is not otherwise public knowledge
         concerning side effects, injury, toxicity or sensitivity reactions and
         incidents and severity thereof associated with commercial and clinical
         uses, studies, investigations or tests (animal and human) directly
         relating to the Product throughout the world, whether or not determined
         to be attributable to the Product.

                  ARTICLE 5 - MANUFACTURE AND SUPPLY OF PRODUCT

 5.1     Exclusive Supplier: 3RP shall manufacture and supply to SAMARITAN, in
         accordance with the terms and conditions set forth herein and in a
         timely fashion, the quantities of the Product ordered by SAMARITAN from
         time to time. Subject to the provisions hereof, SAMARITAN shall order
         from 3RP all of its requirements of the Product for the Territory in
         accordance with the terms and conditions set forth herein.

 5.2     Product Warranty: 3RP warrants that all Product supplied by it to
         SAMARITAN pursuant to this Agreement shall be manufactured, packaged,
         tested, stored, handled and shipped in accordance with the
         Specifications and applicable Regulatory Approval in the Territory. 3RP
         MAKES NO OTHER WARRANTY OF ANY KIND AND EXCLUDES AND DISCLAIMS ANY AND
         ALL IMPLIED WARRANTIES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
         LAW, INCLUDING WITHOUT LIMITATION THOSE CONCERNING THE MERCHANTABILITY
         OF ANY PRODUCT OR ITS SUITABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE
         OR USE.

         ARTICLE 6 - PRODUCTION FORECASTS, ORDERS AND DELIVERIES
  6.1     Forecasts:

(a)            Within thirty (30) days after the Effective Date, SAMARITAN shall
               submit to 3RP a written non-binding estimate of its quarterly
               requirements for the Product for each of the next succeeding six
               (6) Quarters. The forecast shall be updated quarterly on or
               before the fifth (5th) day of the beginning of each Quarter on a
               rolling basis. 3RP shall respond within fifteen (15) business
               days if any additional quantities are included within the
               forecast for any Quarters previously forecasted. If 3RP is unable
               to accept such additional quantities, such additional quantities
               shall be removed form the forecast. SAMARITAN shall have five (5)
               days to respond to 3RP changes. If 3RP does not receive a
               response within five (5) days, it shall be assumed that such
               quantities are approved and acceptable to SAMARITAN.

(b)            The forecast for the most current two (2) Quarters shall be
               binding on the parties regarding the amount of Product to be
               supplied and purchased. The forecast for the remaining four (4)
               Quarters of each rolling forecast is for planning purposes only
               and shall not constitute a commitment to purchase or supply
               Product. In the event that SAMARITAN does not ultimately purchase
               the forecasted quantities for the binding two (2) Quarters, it
               shall nevertheless be obligated to make payment to 3RP for any
               deficient quantities on the basis of the Transfer Price.

 6.2    Purchase Orders: All orders for Product shall be placed using
        SAMARITAN's standard form of purchase order and shall be invoiced using
        3RP's standard form of invoice. Purchase orders shall not contain terms
        which are inconsistent with the terms and conditions of this Agreement
        and shall specify, amongst other things, the desired delivery date,
        which delivery date shall be not less than thirty (30) days from the
        submission date of the purchase order to 3RP. 3RP shall use its best
        efforts to deliver the ordered Product to SAMARITAN within seven (7)
        days of the desired delivery date specified in the purchase order.

 6.3    Delivery of Product: The Product will be prepared for shipment in
        accordance with the reasonable directions of SAMARITAN (or failing such
        reasonable directions in a commercially reasonable manner), the storage
        and transportation conditions forming part of the Product's
        Specifications, cGMP and applicable laws. Title and risk of loss and/or
        damage shall pass to SAMARITAN upon delivery of the Product to
        SAMARITAN's warehouse site in the Territory.

 6.4    Documentation to Accompany Deliveries: All deliveries of Product by or
        on behalf of 3RP shall be accompanied by all documentation required
        under applicable law to import the Product into, and for SAMARITAN to
        offer the Product for sale in, the Territory including, without
        limitation, certificate of analysis and batch manufacturing records
        confirming that the Product supplied hereunder has been manufactured in
        conformity with applicable requirements of the Regulatory Authority.

 6.5    Assistance With Export & Import Laws: SAMARITAN and 3RP shall provide to
        each other such commercially reasonable assistance as the other may
        request relative to the exportation or importation of Product not
        expressly provided in this Agreement.

                      ARTICLE 7 - TRANSFER PRICE AND INSPECTION
  7.1     Purchase Price:

(a)            The purchase price payable by SAMARITAN for Product supplied
               to it shall be as set forth on Schedule "B" annexed hereto (the
               "Transfer Price").

(b)            Except as hereinafter provided, any increase to the Transfer
               Price shall be mutually agreed upon by the parties. If 3RP's
               manufacturing, API or distribution costs for the Product
               materially increase from the date the Transfer Price was last
               established, and 3RP desires to increase the Transfer Price,
               SAMARITAN agrees to discuss and negotiate in good faith with 3RP
               an increase to the Transfer Price to cover 3RP's increased
               costs... The new Transfer Price shall apply to all orders for the
               Product received by 3RP after the sixty (60) day notice period.

<PAGE>

(c)               In addition to the Transfer Price, SAMARITAN shall be
                  responsible for all taxes (including but not limited to
                  value-added and withholding taxes), customs and excise duties
                  with respect to the importation of the Product into the
                  Territory, transfer of the Product within the Territory and
                  promotion, marketing, distribution and sale of the Product
                  within the Territory, whether currently in force or coming
                  into force after the Effective Date of this Agreement
                  (collectively the "Sales Taxes").

(d)               3RP shall submit an invoice to SAMARITAN with each shipment of
                  the Product. Payment for the Product shall be due within sixty
                  (60) days after delivery date of the Product to SAMARITAN. All
                  payments hereunder shall be made in United States Dollars and
                  shall be wire transferred to an account designated by 3RP,
                  from time to time, or paid in accordance with any method
                  agreed in writing by the parties. Distributor shall notify 3RP
                  by facsimile when any payment is made.

(e)               3RP and SAMARITAN shall meet in good faith to discuss and
                  negotiate the Transfer Price, should the selling price to
                  hospitals in Greece as published in the official Greek
                  government gazette not allow SAMARITAN an operational working
                  margin, according to the Greek Industry Standard in similar
                  cases.

 7.2     Inspection: 3RP shall have the right, upon reasonable advance notice
         and at 3RP's expense to inspect and make copies of the records of
         SAMARITAN pertaining to the Product, including but not limited to,
         records relating to Regulatory Approval, pharanacovigilence, product
         liability and the sale and distribution of the Product in the
         Territory.

                            ARTICLE 8 - DISTRIBUTION

 8.1     SAMARITAN's Obligation re Marketing: SAMARITAN shall use reasonable
         commercial efforts to develop a market for the Product in the Territory
         and to actively and continuously promote the sale of the Product in the
         Territory. SAMARITAN shall be solely responsible for the advertising
         and promotion of the Product and shall comply with all applicable laws,
         rules and regulations in that regard including, without limitation,
         applicable Regulatory Authority regulations and guidelines.

  8.2    Pricing: SAMARITAN shall have sole discretion in setting the price for
         the sale of the Product in the Territory, subject to guidelines
         established by the Regulatory Authority.

 8.3     Storage and Handling by SAMARITAN: SAMARITAN shall ensure that the
         Product supplied to it by 3RP pursuant to this Agreement is received,
         handled, stored and delivered in accordance with the Specifications for
         the Product applicable thereto and applicable cGMP and other
         requirements of the Regulatory Authority so that such Product does not
         become adulterated or otherwise cease to meet its Specifications as a
         result of any acts or omissions of SAMARITAN, and its respective
         agents, employees, transporters or those for whom SAMARITAN is
         responsible.

<PAGE>

 8.4     Release of Product by SAMARITAN: SAMARITAN shall conduct or cause to be
         conducted such quality control tests as it deems necessary and/or as
         are required by law (including any rules, regulations and requirements
         of the Regulatory Authority) prior to sale or other release of a
         Product in the Territory.

                    ARTICLE 9 - PRODUCT REJECTIONS AND RETURNS
  9.1     Product Rejection:

(a)            Within sixty (60) days from the date of receipt of delivery
               of Product SAMARITAN shall inspect the Product and shall advise
               3RP in writing (a "Rejection Notice") if a shipment of Product is
               not in conformity with 3RP's obligations hereunder or is
               otherwise defective. If SAMARITAN delivers a Rejection Notice in
               respect of all or any part of a shipment of Product, then 3RP and
               SAMARITAN shall have thirty (30) days from the date of 3RP's
               receipt of such notice to resolve any dispute regarding whether
               all or any part of such shipment of Product fails to conform with
               the Specifications or is otherwise defective. Disputes between
               such parties as to whether all or any part of a shipment rejected
               by SAMARITAN conforms with Specifications not resolved in the
               thirty (30) day period shall be resolved by an independent
               testing laboratory or a consultant (if not a laboratory analysis
               issue) mutually acceptable to SAMARITAN and 3RP, the cost of
               which shall be paid by the party least successful in such dispute
               as determined by such independent testing laboratory or
               consultant.

(b)            In the event any Product is appropriately rejected by
               SAMARITAN as aforesaid, (being Product which does not satisfy the
               Product warranty contemplated in Section 5.2 or are otherwise
               defective as a result of any act by or omission of 3RP or those
               for whom it is responsible), 3RP shall replace such Product with
               conforming goods as quickly as possible, or if requested by
               SAMARITAN, provide a credit to SAMARITAN for the Transfer Price
               previously paid by SAMARITAN to 3RP on account of the Product in
               question. The credit shall be provided immediately following the
               expiry of the period during which 3RP may dispute a Rejection
               Notice as contemplated in Subsection (a) above (unless the
               Rejection Notice is disputed by 3RP, in which event such credit
               shall only be given upon resolution of the dispute). Replacement
               Product shall be delivered to SAMARITAN at no cost to SAMARITAN
               if SAMARITAN has already paid for the rejected Product and not
               received a credit therefore, as aforesaid.

(c)            For purposes of this Agreement once a Product is rejected by
               SAMARITAN, SAMARITAN's obligation to pay for such Product
               shall be suspended until such time as it is determined:

                  (i)      by the independent testing laboratory or consultant
                           that the Product should not have been rejected by
                           SAMARITAN; or

<PAGE>

                   (ii)    by the parties or by an arbitration conducted
                           pursuant hereto or by a final order of a court of
                           competent jurisdiction (which is not subject to
                           further appeal) that no act or omission of SAMARITAN
                           was the cause of the problem.

 9.2     Exclusive Remedy: Subject to Section 10.1 hereof and to its rights, if
         any, to recover expenses associated with a Recall as herein
         contemplated, SAMARITAN hereby acknowledges and agrees that the sole
         remedy of SAMARITAN against 3RP for failure of Product supplied
         hereunder to meet the Product warranty set forth in Section 5.2 hereof
         shall be to require 3RP to replace the Product that does not meet the
         Product warranty hereunder with conforming goods or to provide
         SAMARITAN with a credit for the Transfer Price and that 3RP shall not
         be liable to SAMARITAN for any indirect, special, consequential or
         incidental damages including, without limitation, loss of profits or
         prospective profits of any kind.

 9.3     Return Policy: Other than Product which has been appropriately rejected
         by SAMARITAN pursuant to Section 9.1 above, SAMARITAN shall not have
         the right to return to 3RP any Product purchased by it without 3RP's
         prior written consent.

  9.4    Survival of Provisions:  The  provisions of this Article 9 shall
         survive the  termination or expiration of the Agreement.

               ARTICLE 10 - DAMAGES, INDEMNIFICATION AND INSURANCE

10.1     Indemnity by 3RP: Subject to the limitations set forth in this Section
         10.1 and Section 10.3 hereof, 3RP covenants and agrees to indemnify and
         save harmless and compensate SAMARITAN and its directors, officers and
         employees (collectively, "SAMARITAN Indemnified Parties") from and
         against any and all claims, demands, actions, causes of action, suits,
         proceedings, judgments, liabilities, damages, losses, costs, expenses,
         fines, penalties and other similar assessments, including but not
         limited to reasonable attorney's fees and expenses incurred and
         documented (collectively, "Liabilities") relating to or arising out of
         (i) a breach by 3RP of any of 3RP's representations, warranties,
         covenants or agreements contained in this Agreement; (ii) a claim by
         any Person that the Product as manufactured by 3RP infringes or
         allegedly infringes any proprietary right or other intellectual or
         industrial right of any Person (other than rights of any Person
         relating to patents enforceable in the Territory or the use of any
         name, logo, trade-mark (other than the Marks) or design used by
         SAMARITAN in connection with the packaging and labeling of the
         Product); (iii) the design or inherent safety of the Product (iv) any
         negligence or willful misconduct by 3RP or any 3RP Indemnified Party
         (as defined below); or (v) a regulatory enforcement action, inspection
         of Product or Recall resulting from 3RP's failure to manufacture the
         Product in accordance with the Specifications or resulting from any
         other act or omission of 3RP or those for whom it is responsible;
         provided that, except where the breach arises out of the representation
         or warranty being intentionally false or inaccurate or constitutes a
         willful material breach by 3RP of its duties or obligations hereunder
         or an act or omission constituting gross negligence, the SAMARITAN
         Indemnified Parties shall not be entitled to recover from 3RP any of
         their indirect, special, consequential or punitive damages, including
         loss of profits or loss or damage to goodwill or reputation. SAMARITAN
         shall hold the benefit of this indemnity in trust for those SAMARITAN
         Indemnified Parties who are not parties to this Agreement.

<PAGE>

10.2    Indemnity by SAMARITAN: Subject to the limitations set forth in this
        Section 10.2 and in Section 10.3 hereof, SAMARITAN covenants and agrees
        to indemnify and save harmless and compensate 3RP and its respective
        directors, officers and employees {collectively, "3RP Indemnified
        Parties") from and against any and all Liabilities relating to or
        arising out of (i) a breach by SAMARITAN of any of SAMARITAN's
        representations, warranties, covenants or agreements contained in this
        Agreement; (ii) the receiving, storage, handling, marketing,
        distribution, sale or delivery of the Product by SAMARITAN (except to
        the extent that 3RP is responsible therefor pursuant to Section 10.1
        above); (iii) any claim by any Person that any trade mark, trade dress,
        logo, name or design used by SAMARITAN in labeling or packaging of the
        Product (other than the Marks) or, in the case of trade dress, the
        manufacture of the Product in accordance the directions of SAMARITAN,
        infringes any trade-mark or other intellectual property right of any
        Person; (iv) any death or bodily injury to any Person or any damage to
        property arising out of, or any regulatory enforcement action,
        inspection of Product or Recall resulting from a breach by SAMARITAN of
        its obligations hereunder; or (v) any negligence or willful misconduct
        of SAMARITAN or of an SAMARITAN Indemnified Party; provided that, except
        where the breach arises out of the representation or warranty being
        intentionally false or inaccurate or constitutes a willful material
        breach by SAMARITAN of SAMARITAN's duties or obligations hereunder or an
        act or omission constituting gross negligence, the 3RP Indemnified
        Parties shall not be entitled to recover from SAMARITAN any indirect,
        special, consequential or punitive damages, including loss of profits or
        loss or damage to goodwill or reputation. 3RP shall hold the benefit of
        this indemnity in trust for those 3RP Indemnified Parties who are not
        parties to this Agreement.

10.3    Indemnification Procedure for Third Party Claims: Upon the assertion by
        any third party of a claim against a 3RP Indemnified Party or an
        SAMARITAN Indemnified Party that may give rise to right of
        indemnification under this Agreement, the party who, or whose directors,
        officers or employees, is claiming a right to indemnification (the
        "Indemnified Party") shall give prompt notice to the party alleged to
        have the duty to indemnify (the "Indemnifying Party") of the existence
        of such claim (provided that the failure to give such notice in timely
        fashion shall not release the Indemnifying Party of its obligations of
        indemnification hereunder except to the extent that the Indemnifying
        Party has been prejudiced thereby) and shall give the Indemnifying Party
        reasonable opportunity to control, defend and/or settle such claim at
        its own expense and with counsel of its own selection; provided,
        however, that the Indemnified Party shall, at all times, have the right
        to fully participate in such defense at its own expense with separate
        counsel and, provided that both parties to the extent that they are not
        contractually or legally excluded therefrom, or otherwise prejudiced in
        a legal position by so doing, shall cooperate with each other and with
        their respective insurers in relation to the defense of such third party
        claim. The Indemnifying Party shall consult with the Indemnified Party
        with respect to settlement of any claim. The Indemnifying Party shall
        have the right to settle any claim without the consent of the
        Indemnified Party, provided that the Indemnified Party is
        unconditionally released from such claim and it is not otherwise
        prejudiced by the terms of settlement (including, without limitation,
        that no obligations in addition to those set forth herein are imposed
        upon the Indemnified Party). In the event the Indemnifying Party elects
        to defend such claim, the Indemnified Party may not settle such claim
        without the prior written consent of the Indemnifying Party. If the
        Indemnifying Party shall, within a reasonable time after such notice has
        been given, fail to defend, compromise or settle such claim, (or
        thereafter fails to diligently defend such claim) then the Indemnified
        Party shall have the right to defend, compromise or settle such claim
        without prejudice to its rights of indemnification hereunder.
        Notwithstanding the foregoing, in the event of any dispute with respect
        to indemnity hereunder, each party shall be entitled to participate in
        the defense of such claim and to join and implead the other in any such
        action.

<PAGE>

10.4    Insurance: During the term of this Agreement and for a period of not
        less than thirty-six (36) months following the termination of this
        Agreement, each of SAMARITAN, on the one hand, and 3RP, on the other
        hand, shall carry or be subject to coverage under (as a named insured
        under its own policy or a policy of its parent corporation), at their
        own cost and expense, comprehensive general liability insurance,
        including product liability and contractual liability insurance in an
        amount of not less than $2 Million EURO in the aggregate and $1 Million
        EURO per occurrence, which insurance will be written on a claims made
        policy form with an insurance carrier reasonably acceptable to the other
        party. Each of 3RP and SAMARITAN shall, at the request of the other,
        provide evidence to such requesting party of compliance with its
        insurance obligations under this Section and evidence of renewals of any
        such policy, from time to time. Each party shall cause the other to be
        named as an additional insured for death, bodily injury and property
        damage caused by those acts or omissions for which such party is
        responsible hereunder under the product liability insurance policy or
        policies to be obtained and maintained by such party pursuant hereto.

10.5    Survival: The provisions of this Article 10 shall survive termination or
        expiration of this Agreement.

                        ARTICLE 11 - TERM AND TERMINATION

11.1    Term: The term of this Agreement shall be for ten (10) years commencing
        on the Effective Date, unless earlier terminated in accordance with the
        provisions of this Agreement. Thereafter, this Agreement shall
        automatically renew for successive periods of five (5) years each unless
        SAMARITAN or 3RP gives written notice of termination to the other at
        least twelve (12) months prior to the expiration of the any tern,
        subject to earlier termination as provided in this Agreement.

11.2    Transfer of Approvals: Upon any termination or expiration of this
        Agreement SAMARITAN shall immediately assign or cause to be transferred
        to 3RP or its nominee all Regulatory Approvals and all licenses,
        registered uses, distribution arrangements and other rights SAMARITAN
        may have acquired hereunder with respect to the Product, including the
        Marks, and SAMARITAN shall have no further rights thereto. To the
        extent assignment or transfer of the Regulatory Approvals and all
        licenses, registered uses, distribution arrangements and other rights is
        not permitted under local law in the Territory, SAMARITAN shall
        cooperate in the cancellation or abandonment of same, and in the
        reissuance thereof to 3RP or its nominee. SAMARITAN shall not after
        termination or expiration of this Agreement use in the Territory any
        name or marks confusingly similar to the Marks.

<PAGE>

11.3    Material Breach: 3RP or SAMARITAN may, by notice in writing to the
        other, terminate this Agreement, if such other party shall have breached
        any of its duties or obligations under this Agreement and such default
        continues unremedied for a period of thirty (30) days following receipt
        of written notice of such default (or, if such default is not a payment
        or repayment default and is capable of being remedied, but is not
        reasonably capable of being remedied within such thirty (30) day period,
        such longer period of time as is reasonable in the circumstances, not
        exceeding ninety (90) days in the aggregate, provided that the
        defaulting party has, within such thirty (30) day period, commenced and
        thereafter actively and diligently pursues the remedying of such
        default). Notice of termination may only be given during the period that
        the default in question continues. In the event that a party has been
        given notice pursuant to this Section 11.2 and such party disputes the
        alleged breach or the continuation of such breach beyond the cure
        period, the dispute shall be submitted to arbitration pursuant to
        Article 15 hereof, and this Agreement shall continue in full force until
        such time as the arbitrator renders his decision. The arbitrator shall
        determine whether or not there has been a breach and/or whether or not
        the same has been remedied within the required cure period. Termination
        of this Agreement pursuant hereto shall be without prejudice to any
        other right or remedy the party terminating this Agreement may have
        against the defaulting party arising out of the breach in question
        including the right to obtain compensation for its damages (provided
        that such right shall be subject to the limitations set forth in Article
        10 hereof).

11.4    Bankruptcy or Insolvency: 3RP or SAMARITAN shall have the right to
        terminate this Agreement upon written notice to the other in the event
        that any one or more of the following events shall become applicable to
        such other party (herein referred to as the "Party"):
(a)              an order is made or a resolution or other action of such Party
                 is taken for the dissolution, liquidation, winding up or other
                 termination of its legal existence;
(b)              the Party commits a voluntary act of bankruptcy, becomes
                 insolvent, makes an assignment for the benefit of its creditors
                 or proposes to its creditors a reorganization, arrangement,
                 composition or readjustment of its debts or obligations or
                 otherwise proposes to take advantage of or shelter under any
                 statute in force in the United States or in the Territory for
                 the protection of debtors;
(c)              a proceeding is commenced to have such Party declared bankrupt
                 or to have a receiver appointed in respect of such Party or a
                 substantial portion of its property and such proceeding is not
                 fully stayed or dismissed within thirty (30) days after such
                 commencement;

<PAGE>

(d)               a receiver or a receiver and manager of any of the assets of
                  such Party is appointed and such receiver or receiver and
                  manager is not removed within thirty (30) days of such
                  appointment; or
(e)               such Party ceases or takes steps to cease to carry on its
                  business.

11.5    No Regulatory Approval: Either party may terminate this Agreement if
        SAMARITAN is denied, is otherwise unable to obtain or maintain, the
        Regulatory Approval.

11.6    Other  Contractual  Terminations:  3RP and SAMARITAN may terminate this
        Agreement under other Sections of this
        Agreement as may be specifically provided under those Sections.

11.7    Survival: Any cause of action for breach of contract shall survive the
        termination or expiration of this Agreement. The termination or
        expiration of this Agreement shall not affect any right or obligation of
        3RP or SAMARITAN existing prior to the effective date of termination or
        expiration and which is expressly set forth hereunder as surviving
        termination. Without limiting the generality of the foregoing,
        termination or expiration of this Agreement shall not affect any right,
        duty or obligation which is expressly stated hereunder as surviving
        termination.

            ARTICLE 12 - REGULATORY MATTERS AND ACCESS TO FACILITIES

12.1    Retention of Technical Records and Samples: Each of 3RP and SAMARITAN
        shall keep such samples and such records (or copies thereof) in respect
        of the Product being manufactured, supplied or distributed by it as are
        required by the applicable Specifications and/or applicable law of the
        Territory for such period of time as may be required thereunder. 3RP
        shall permit SAMARITAN to have access to such samples and original
        records as are required to be maintained by 3RP at all reasonable times
        upon prior reasonable notice and shall, upon written request, promptly
        provide SAMARITAN with a copy of all such records.

12.2    Co-operation re Product Safety: 3RP and SAMARITAN shall promptly advise
        the other of any safety or toxicity problem of which such party becomes
        aware regarding the Product (or any intermediates or other ingredients
        or processes used in the manufacture thereof) being supplied or
        distributed by it.

12.3    Regulatory Authority Correspondence: 3RP and SAMARITAN shall, subject to
        Section 12.5 hereof, provide the other with a copy of any correspondence
        or notices received by such party from the Regulatory Authority relating
        to or referring to the Product within ten (10) days of receipt and a
        copy of any response to any such correspondence or notices with ten (10)
        days of making a response. 3RP shall notify SAMARITAN promptly of any
        materially adverse inspections by the Regulatory Authority which pertain
        to the Product or to the facility where the Product is being
        manufactured and provide SAMARITAN with a copy of the report.

<PAGE>

12.4    Notification of Adverse Events:

(a)               3RP shall notify SAMARITAN promptly of any pending or
                  threatened litigation or governmental investigation,
                  proceeding or action involving the Product or the facility
                  where the Product is being manufactured of which 3RP becomes
                  aware and of any defective, adulterated or misbranded Product
                  or any other information which may suggest that the Product is
                  or may be defective, adulterated or misbranded or fail to meet
                  the Specifications or to maintain the stability as indicated.
                  3RP shall notify SAMARITAN promptly of any material product
                  quality complaints which it receives from customers of
                  SAMARITAN or others concerning the Product.

(b)               SAMARITAN shall notify 3RP:

               (i)  of any customer complaints or alleged adverse drug reaction
                    relating to a Product within the meaning of the FDA Safety
                    Information and Adverse Event Reporting Program (21 CFR,
                    Part 20) (an "ADR" which, on the Effective Date, means a
                    noxious and unintended response to the Product, which occurs
                    at dosages normally used or tested for the diagnosis,
                    treatment or prevention of a disease or the modification of
                    an organic function) promptly following their receipt by
                    SAMARITAN (but in any event within ten (10) days of receipt
                    thereof, except in the case of a Serious ADR [as defined
                    below] in which event SAMARITAN shall notify 3RP of same
                    within seventy-two (72) hours, which latter notification
                    shall be by telephone with a facsimile confirmation
                    immediately following; or

               (ii) of any Regulatory Authority complaints or complaints of any
                    other governmental or regulatory body, agency or official in
                    the Territory within five (5) days, except on weekends and
                    holidays.

         For purposes of this Agreement "Serious ADR" shall have the meaning
         attributed thereto under the FDA Safety Information and Adverse Event
         Reporting Program (21 CFR, Part 20), from time to time, which, on the
         Effective Date means a noxious and unintended response to a drug that
         occurs at any dosage and that is fatal or life-threatening, results in
         persistent or significant disability/incapacity, requires or prolongs
         inpatient hospitalization, necessitates medical or surgical
         intervention to preclude permanent impairment of a body function or
         permanent damage to a body structure, or is a congenital anomaly. 3RP
         shall notify SAMARITAN in the manner and within the time periods
         hereinbefore contemplated of any Regulatory Authority complaint (or of
         the complaint of any other governmental body, agency or official in the
         Territory) relating to the Product following their receipt by 3RP.

(c)      SAMARITAN shall be responsible for filing any necessary reports
         required by the Regulatory Authority in accordance with the applicable
         laws of the Territory.

<PAGE>

(d)      To enable SAMARITAN to respond to any requirements of the Regulatory
         Authority in connection with a complaint or ADR, 3RP agrees to
         investigate any complaint or ADR forwarded to it by SAMARITAN and to
         respond  thereto to SAMARITAN in writing as promptly as reasonably
         possible and, in no event, later than thirty (30) days after receipt of
         the ADR or complaint from SAMARITAN. In addition, 3RP shall provide
         SAMARITAN with a copy of any correspondence, reports, or other
         documents relating to a complaint or ADR received by 3RP relating to
         the Product promptly following the receipt thereof and shall also
         provide to SAMARITAN 3RP's response thereto within a reasonable period
         following generation of such document by 3RP. Upon the request of 3RP,
         SAMARITAN shall use reasonable commercial efforts to retrieve and
         deliver to 3RP such samples of the Product which are the object of a
         complaint or ADR as 3RP may reasonably request to enable 3RP to conduct
         such tests, studies and investigations as it determines to be necessary
         to respond to such ADR or complaint or to take appropriate corrective
         action.

12.5     Recalls:

(a)              In the event that SAMARITAN shall be required (or shall
                 voluntarily decide) to initiate a recall, product withdrawal or
                 field correction of any Product (a "Recall"), whether or not
                 such Recall has been requested or ordered by the Regulatory
                 Authority (or any other governmental body, agency or official
                 having jurisdiction in the Territory) or by a court, SAMARITAN
                 shall notify 3RP and 3RP shall fully co-operate with SAMARITAN
                 in notifying their customers to return all such Product and
                 shall follow any other instructions provided by SAMARITAN.

(b)              In the event that 3RP believes that a Recall may be necessary
                 and/or appropriate, prior to taking any action 3RP shall
                 immediately notify SAMARITAN and 3RP and SAMARITAN shall
                 co-operate with each other in determining the necessity and
                 nature of the action to be taken.

(c)              With respect to any Recall, SAMARITAN shall make all contacts
                 with the Regulatory Authority, or other applicable party, and
                 shall be responsible for co-ordinating all of the necessary
                 activities in connection with such Recall and 3RP and SAMARITAN
                 shall each co-operate with the other in recalling the affected
                 Product.

(d)              In the event that a Recall results solely from any cause or
                 event arising from the  manufacture,  testing, storage,
                 handling,  packaging,  labeling or shipping of the Product by
                 3RP or those for whom it is responsible or other cause or event
                 attributable to 3RP or those for whom it is responsible,  3RP
                 shall be  responsible  for all expenses of such Recall.  In the
                 event that a Recall results solely from any cause or event
                 arising from the receiving,  storage, handling,  marketing or
                 distribution of the  Product  by  SAMARITAN  or  those  for
                 whom it is  responsible  or  other  cause or event attributable
                 to SAMARITAN,  SAMARITAN  shall be responsible  for all
                 expenses of such Recall.  In all other  cases the parties shall
                 share the  Recall  Expenses  equally  and each  party  shall
                 reimburse the other party for 50% of the Recall Expenses
                 incurred by such other party.

<PAGE>

(e)               For purposes of this Agreement, Recall expenses shall include,
                  but not be limited to, the expenses of notification and
                  destruction or return of the recalled Product, as the case may
                  be, and SAMARITAN and 3RP's reasonable out-of-pocket costs in
                  connection with such Recall including but not limited to
                  reasonable attorney's fees and expenses and credits and recall
                  expenses claimed and paid to customers (the "Recall
                  Expenses"). Each of the parties shall use its reasonable best
                  efforts to minimize the Recall Expenses which it incurs and
                  shall provide to the other, upon request, reasonable evidence
                  of the out-of-pocket expenses being claimed by it.

(f)               All communications relating to a Recall shall be held in
                  confidence and shall be subject to the terms of Article 13
                  hereof.

                          ARTICLE 13 - CONFIDENTIALITY

13.1    Confidential Nature of Agreement: Each of the parties hereto agrees
        that, without the prior written consent of the other, or except as may
        be required by law or court order, the terms of this Agreement shall
        remain confidential and shall not be disclosed to any Person other
        employees and professional advisers of such party or its Affiliates who
        reasonably require knowledge of the existence or terms of this Agreement
        and who are bound to such party or its Affiliates by a like obligation
        of confidentiality. Such employees and advisors will be advised of the
        nature and existence of the confidentiality undertakings of this
        Agreement and of the applicability of such undertakings to them and will
        agree to be bound hereby.

13.2    Duty of Confidentiality: Each of 3RP and SAMARITAN agrees to hold in
        trust and confidence (and to cause its Affiliates to hold in trust and
        confidence) for the benefit of the other party (and its Affiliates) all
        Confidential Information of such other party and its Affiliates and each
        further agree to safeguard, and to cause its Affiliates to safeguard,
        the Confidential Information of the other (or its Affiliates) to the
        same extent that it does with its own confidential information. Neither
        party will, without the express written consent of the other, directly
        or indirectly, use (or authorize, permit or suffer any of its Affiliates
        to use) any Confidential Information of the other party or of its
        Affiliates for any purpose other than to implement the provisions of
        this Agreement (including, without limitation, to obtain the Regulatory
        Approval for the Product) or in regulatory proceedings or in litigation.
        Neither party will disclose Confidential Information to any Person,
        other than (i) its employees or other representatives or those of its
        Affiliates who have a need to know such information to fulfill the
        provisions and intent of this Agreement (where such provisions and
        intent cannot properly be fulfilled without such disclosure) and who
        have been informed of the confidential nature of the information and
        have agreed to be bound by the terms hereof, and (ii) a Regulatory
        Authority. Each of 3RP and SAMARITAN shall use its best efforts to
        prevent unauthorized use or disclosure of the Confidential Information
        of the other and shall use protective measures no less stringent than
        those used by it in its own business to protect its own confidential
        information.

<PAGE>

13.3    Compulsory Disclosures: In the event that either 3RP or SAMARITAN (or
        its Affiliate) shall be legally compelled or required by a court of
        competent jurisdiction to disclose all or any part of the Confidential
        Information of the other (or its Affiliates), it shall provide notice
        thereof to the other prior to such disclosure so that such other party
        (or its Affiliate) may determine whether or not to seek, at its own
        expense, a protective order or any other appropriate remedy. If a
        protective order or other appropriate remedy is not obtained before such
        disclosure is required, the party required to make disclosure will
        disclose only those portions of the Confidential Information in question
        which it is advised by written opinion of counsel (which opinion shall
        be addressed to such party and to the other party), it is legally
        required to disclose and will cooperate with the efforts of the other
        party at the other party's expense, to obtain reliable assurances that
        confidential treatment will be accorded such Confidential Information.

13.4    Survival: The obligations of confidentiality contained herein shall
        survive the termination of this Agreement.

                          ARTICLE 14 - LICENSE OF MARKS

14.1    Marks: During the term of this Agreement, SAMARITAN shall have the
        non-exclusive right to use the trademarks, logos and brand names
        ("Marks") belonging to 3RP in connection with the promotion, sale,
        marketing and distribution of the Product. SAMARITAN acknowledges that
        the Marks and any registrations thereof are and shall remain the
        property of 3RP and SAMARITAN disclaims any rights to such Marks and
        registrations other than the rights granted pursuant to this Section
        14.1 and will not represent in any way that it has any right or title to
        the ownership of the Marks or registrations thereof.

(a)              All Product and all labeling, advertising and promotional
                 material in connection therewith shall feature the applicable
                 Marks. SAMARITAN will first obtain the written approval of 3RP
                 of the form and manner in which the Marks will be used upon, in
                 connection with, or in relation to, the Product, labels,
                 package inserts, containers, advertisements and other
                 materials.

(b)              SAMARITAN shall, upon 3RP's request, assist 3RP in any action
                 reasonable necessary or desirable to protect the Marks.
                 SAMARITAN shall as soon as practicable notify 3RP of any
                 apparent infringement by a third party of any of the Marks.

(c)              After consultation with 3RP, SAMARITAN shall immediately
                 discontinue the use of any of the Marks upon notice from a
                 third party that such use is or is alleged to be an
                 infringement of such third party's trademark rights and all
                 liability arising out of SAMARITAN's use of any such Mark after
                 such Notice shall be borne by SAMARITAN.

<PAGE>

                         ARTICLE 15 - DISPUTE RESOLUTION

15.1    Dispute Resolution Committee: If any dispute or question (in this
        Article called a "Dispute") shall arise between the parties during the
        term of this Agreement concerning the interpretation of this Agreement
        or any part hereof, the parties shall in good faith attempt to resolve
        such Dispute promptly and in an amicable manner under the following
        informal dispute resolution procedure. If a Dispute arises which is not
        resolved by the operational personnel involved, the Chief Executive
        Officer of each party or such other senior operations manager of each
        party as is designated by such party from time to time to serve in such
        capacity (in this Section collectively called the "Dispute Resolution
        Committee") shall be notified. The Dispute Resolution Committee, made up
        of equal representation, shall meet within ten (10) days of being
        notified of a Dispute, or at such time as is mutually agreed by the
        parties, and shall conduct negotiations in good faith in an effort to
        resolve the Dispute.

15.2    Arbitration: In the event the Dispute Resolution Committee is unable to
        resolve a Dispute within fifteen (15) days of the first written
        notification of the Dispute, then such Dispute shall be resolved by
        arbitration. Any controversy or claim arising out of or related to this
        contract shall be determined by arbitration in accordance with the
        International Arbitration Rules of the international Centre for Dispute
        Resolution. The arbitration shall be administered by the International
        Centre for Dispute Resolution (ICDR) and shall take place in New York,
        New York, United States of America. The parties agree: (a) one
        arbitrator shall determine the resolution of the Dispute; (b) the
        arbitrator shall be chosen from a list provided by the ICDR; (c) the
        arbitration itself and all documentation will be in the English
        language; (d) the decision of the arbitrator shall be binding and
        non-appealable; and (e) the cost of the arbitration shall be shared
        equally by each party and the responsibility for each party's related
        expenses, including attorneys fees, shall be absorbed by each respective
        party.

15.3    Pre-Conditions: Subject only to Section 15.4, no Dispute shall be the
        subject of arbitration or any other formal proceeding between the
        parties before being considered by the Dispute Resolution Committee as
        set forth in this Article.

15.4    Equitable Relief: Either party may seek injunctive or equitable relief
        without complying with the above described procedures.

               ARTICLE 16 - GENERAL CONTRACT TERMS AND CONDITIONS

16.1    Notice: Subject to the express provisions of this Agreement, any notice
        required or permitted to be given under this Agreement shall be
        sufficiently given if in writing and delivered by facsimile (with
        confirmation of transmittal) or overnight courier (with confirmation of
        delivery), as well as by prepaid registered mail (with return receipt
        requested) or hand delivery to the appropriate party at the address set
        forth below, or at such other address or to the attention of such other
        individual as such party may from time to time specify for that purpose
        in a notice similarly given at least fifteen (15) days prior to the date
        such change is to become effective:

<PAGE>

        To SAMARITAN at:

        41 Skoufa Street Athens -
        10673 Greece
        Attention: Dr. Christos Dakas
        Fax Number: 30 2103392062
        Phone Number: 30 6948233032

        To 3RP at:

        312 Commerce Park Drive,
        Cranberry Township, Pennsylvania, United
        States of America, 16066.

        Attention: Legal Department
        Fax Number:                         (724) 778-6101
        Phone Number:                       (724) 778-6100

        Any such notice shall be deemed delivered (i) if sent by mail, as
        aforesaid, on the date upon which the return receipt is signed or
        delivery is refused or the notice is designated by the postal
        authorities as not deliverable, as the case may be, (ii) if sent by
        facsimile, as aforesaid, when sent (with confirmation of receipt), and
        (iii) if sent by courier or hand delivered, as aforesaid, when received

16.2    Force Majeure: Neither party shall be considered to be in default in
        respect of any obligation hereunder if failure of performance shall be
        due to Force Majeure (as hereinafter defined). If either party is
        affected by a Force Majeure event such party shall, give prompt notice
        to the other party stating the nature of the event, its anticipated
        duration and any action being taken to avoid or minimize its effect. The
        suspension of performance shall be of no greater scope and no longer
        duration than is required by such Force Majeure event and the
        non-performing party shall use commercially reasonable efforts to remedy
        its inability to perform. The obligation to pay money in a timely manner
        is absolute and shall not be subject to the Force Majeure provisions,
        except to the extent payment is prohibited by governmental rule or
        regulations other than rules or regulations incident to bankruptcy or
        insolvency proceedings of a party. Force Majeure shall mean a cause
        beyond the reasonable control and without the fault or negligence of a
        party including, but not limited to, explosion, flood, war (whether
        declared or otherwise), accident, labor strike or other labor
        disturbance, inability to obtain materials or services, sabotage, acts
        of God, newly enacted legislation, newly issued orders or decrees of any
        Court and any binding act or order of any governmental agency.
        Notwithstanding anything in this Section, the party to whom performance
        is owed but to whom it is not rendered because of an event of Force
        Majeure as contemplated in this Section shall, after the passage of one
        hundred eighty (180) days and while such event continues, have the
        option to immediately terminate this Agreement upon written notice to
        the other party hereto.

<PAGE>

16.3    Further Assurances: Each party agrees to execute and deliver any and all
        such other and additional instruments and documents and do any and all
        such other acts and things as may be necessary or expedient to
        effectuate more fully this Agreement and to carry out the business
        contemplated by this Agreement.

16.4    Entire Agreement: This Agreement and the Schedules attached hereto
        contains the entire Agreement and understanding of the parties with
        respect to its subject matter and supersedes all negotiations, prior
        discussions and any agreements relating to the Product. This Agreement
        may not be amended or modified except by a written instrument signed by
        the parties.

16.5    Waiver: Any representation, warranty, covenant, term or condition of
        this Agreement which may legally be waived, may be waived, or the time
        of performance thereof extended, at any time by the party hereto
        entitled to the benefit thereof, and any term, condition or covenant
        (including, without limitation, the period during which any condition is
        to be satisfied or any obligation performed) may be amended by the
        parties hereto at any time. Any waiver, extension or amendment shall be
        effective only if it is in writing and signed by the party giving it,
        and only in the specific instance and for the specific purpose for which
        it has been given. No failure on the part of any party to exercise, and
        no delay in exercising, any right under this Agreement shall operate as
        a waiver of such right. No single or partial exercise of any such right
        shall preclude any other or further exercise of such right or the
        exercise of any other right.

16.6    Counterparts: This Agreement may be executed in identical duplicate
        copies exchanged by facsimile transmission. The parties agree to execute
        two identical original copies of the Agreement after exchanging signed
        facsimile or electronic versions. Each identical counterpart shall be
        deemed an original, but all of which together shall constitute one and
        the same instrument.

16.7    No Third Party Rights: The provisions of this Agreement are for the
        exclusive benefit of the parties to this Agreement and no other Person
        (including, without limitation, any creditor of any party to this
        Agreement) shall have any right or claim against any party to this
        Agreement by reason of those provisions or be entitled to enforce any of
        those provisions against any party to this Agreement.

16.8    Severability of Provisions: If, for any reason whatsoever, any term,
        covenant or provision of this Agreement or the application thereof to
        any party or circumstance or in any jurisdiction is to any extent held
        or rendered invalid, unenforceable or illegal, then such term, covenant
        or condition (a) is deemed to be independent of the remainder of this
        Agreement and to be severable and divisible therefrom and its
        invalidity, unenforceability or illegality shall not affect, impair or
        invalidate the remaining provisions hereof(.), and (b) continue to be
        applicable and enforceable to the fullest extent permitted by law in
        every other jurisdiction and against any party and circumstances other
        than those as to which or in respect of which it has been held or
        rendered unenforceable or illegal.

<PAGE>

16.9    Assignment: Neither party shall assign or otherwise transfer this
        Agreement without the written consent of the other party, which consent
        shall not be unreasonably withheld; provided, however, that 3RP may
        assign this Agreement, in whole, or in part, to an Affiliate, purchaser
        or transferee of all or substantially all of 3RP's business relating to
        the Product without the consent of SAMARITAN. SAMARITAN may distribute
        the Product through its Affiliates within the Territory and guarantees
        the performance of any such Affiliates in relation to this Agreement.
        Any purported assignment in violation of the preceding sentence shall be
        void. Any permitted assignee shall assume all obligations of its
        assignor under this Agreement. No assignment shall relieve a party of
        responsibility for the performance of any obligations that have already
        accrued.

16.10    Non Contravention: Each party represents and warrants that the
         execution, delivery and performance of this Agreement by it will not
         contravene any other contract or agreement to which it is a party or by
         which it is bound.

16.11    Remedies Cumulative: The rights and remedies provided in this Agreement
         to a non-defaulting party shall be deemed cumulative, and the exercise
         of one of such remedies shall not operate to bar the exercise of any
         other rights and remedies reserved to a non-defaulting party under the
         provisions of this Agreement or given to a non-defaulting party at law
         or in equity (subject to the limitations contemplated in Article 10
         hereof).

16.12    Binding Effect: This Agreement and all of the provisions hereof shall
         be binding upon and inure to the benefit of the parties hereto, their
         Affiliates, and each of their successors and permitted assigns.

16.13    Announcements: Neither party shall make any public announcement or
         press release concerning the existence of this Agreement or the
         relationship of the parties created hereby without the prior written
         consent of the other party, which consent shall not be unreasonably
         withheld or unduly delayed. Subject to the foregoing, any such
         announcement or press release shall only be made at such time and in
         such manner as the parties may agree upon.

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be
executed by its duly authorized officer as of the date first above written.

SAMARITAN PHARMACEUTICALS, SA

By: /s/ Dr. Christos Dakas
------------------------------------------------------------
        Dr. Christos Dakas, Managing Director

THREE RIVERS PHARMACEUTICALS, LLC

By: /s/  Patrick Kerrish
----------------------------------------------------------
         Patrick Kerrish, Sr. VP, Business Development

<PAGE>

                                  SCHEDULE "A"

                                   DEFINITIONS

"Affiliate" means, in relation to SAMARITAN, 3RP or a Person, any Person which,
directly or indirectly, controls, is controlled by or is under common control
with such Person. For purposes of this definition, the term `"control" (as used
in the terms "controls", "controlled by" and "under common control") means
either (i) holding 50% or more of the voting securities of such Person or, (ii)
in the case of a Person that has no outstanding voting securities, having the
right to 50% or more of the profits of such Person or having the right in the
event of dissolution to 50% or more of the net assets of such Person or, (iii)
the power to direct or cause the direction of the management and policies of
such Person, whether pursuant to the ownership of voting securities, by contract
or otherwise;

"Business day" means a day other than a Saturday, a Sunday or a day which is a
statutory holiday in the Territory or the United States of America;

"cGMP" means the current Good Manufacturing Practices of the Territory as
applicable to the Product (as in effect from time to time);

"Competing Product" means a pharmaceutical product which is in the same dosage
form, has the same active ingredient, the same strength and is for the same
indication as the Product and which, in the case of the restrictions applicable
to SAMARITAN hereunder, is manufactured and supplied by or purchased or acquired
from any Person other than 3RP;

"Confidential Information" shall mean information disclosed to or obtained by
one party from another party (including information obtained by one party as a
result of access to the facilities of the other party) either prior to or during
the term of this Agreement which is non-public, confidential or proprietary in
nature (including, without limitation, trade secrets, financial data, product
information, manufacturing methods, market research data, marketing plans,
identity of customers, or product information [including, without limitation, in
the case of 3RP, the nature and source of raw materials, Product formulation and
methods of producing, testing and packaging the Product]) and which relates to
the disclosing party's past, present or future research, development or business
activities. Confidential Information shall not, however, include information
that a party can demonstrate by written evidence:
(i)               is in the public domain (provided that information in the
                  public domain has not and does not come into the public domain
                  as a result of a breach by a party hereto of its obligations
                  of confidentiality contained herein;
(ii)              is known by the receiving party prior to disclosure by the
                  other party; or
(iii)             which has been developed by the receiving party independent of
                  any disclosure by the other party;
(iv)              is subsequently, lawfully and in good faith obtained by the
                  receiving party on a non-confidential basis from a third party
                  as shown by documentation sufficient to establish the third
                  party as the source of the information, provided that such
                  third party was not under an obligation to treat such
                  information in a confidential manner and had a lawful right to
                  make such disclosure;

<PAGE>

"FDA" means the United States Food and Drug Administration.

"Person" shall be broadly interpreted and shall include an individual,
partnership, joint venture, association, corporation, company and any other form
of business organization, government, regulatory or governmental agency,
commission, department and instrumentality;

"Product" means 3RP's proprietary AMPHOCIL(R) brand of Amphotericin B with
sodium cholesteryl sulphate as manufactured and supplied by 3RP to SAMARITAN
pursuant hereto;

"Quarter" means a complete period consisting of three months from January to
March, April to June, July to September and October to December, all inclusive.

"Regulatory Approval" means receipt of final approval from applicable regulatory
authorities which permit the importation and commercial sale of the Product in
the Territory;

"Regulatory Authority" means the applicable government ministry, department or
regulatory body responsible in the Territory for issuing Regulatory Approval or
licenses and/or for enacting, monitoring and/or enforcing the applicable laws
relating to the importation and sale of pharmaceutical products in the
Territory;

"Specifications" means the terms and conditions applicable to the Product as
contained in the application filed with the Regulatory Authority and the terms
and conditions applicable to the final approval covering such Product issued by
the Regulatory Authority, as the same may be supplemented from time to time;

"Territory" means the countries Greece and Cyprus.EXHIBIT 10.16

                             DISTRIBUTION AGREEMENT

This distribution agreement (the "Agreement") is made and entered into by and
between:
L. MOLTENI & C. dei F.lli Alitti Societa di Esercizio S.p.A., a company existing
and organized under the laws of Italy, with registered office at Strada Statale
67 (Localita Granatieri), Scandicci, Florence, Italy, represented by Mr.
Federico Seghi-Recli, in his capacity as Managing Director, (hereinafter
referred to as "MOLTENI");
                                                                 on the one part
                                       and
SAMARITAN PHARMACEUTICALS EUROPE S.A., a company existing and organized under
the laws of Greece, with registered office at 41 Skoufa Street, Athens (Greece),
represented by Dr. Christos Dakas, in his capacity as Managing Director,
(hereinafter referred to as "SAMARITAN"),

                                                              on the other part
(MOLTENI and SAMARITAN are herein jointly referred to also as the "Parties" and
each individually as a "Party", as the case may be.)

                                     WHEREAS

A)        MOLTENI is engaged in the manufacturing, marketing and distribution of
          pharmaceutical products worldwide and is, among others, holder of the
          relevant marketing authorizations of the Products (as defined
          hereinafter) in Italy and owner of the Trademarks (as defined
          hereinafter).
B)        SAMARITAN is a company engaged in the distribution of pharmaceutical
          products in the Greek and Cypriot territory, is duly organized and
          qualified to performs all acts required herein and possesses the
          necessary organization, manpower and experience ensure the
          distribution of the Products (as defined hereinafter) in the Territory
          (as defined hereinafter) under the terms and conditions contained in
          this Agreement.
C)        SAMARITAN wishes to be appointed as exclusive distributor of the
          Products in the Territory and MOLTENI intends to grant the exclusive
          distribution of the Products in the Territory to SAMARITAN, pursuant
          to the terms and Products in the Territory to SAMARITAN, pursuant to
          the terms and conditions set forth herein.
D)        On 1 January 2007 the Parties entered into an agreement which governs
          the mutual obligations to keep confidential certain information
          disclosed under this Agreement (the "Confidentiality Agreement").

<PAGE>

 NOW, THERETOFORE, on the basis of the foregoing Recitals, which together with
the Annexes attached hereto form an integral and essential part of this
Agreement, and on the basis of the mutual obligations and conditions set forth
herein, MOLTENI and SAMARITAN agree as follows.

1.             CERTAIN DEFINITIONS

(i)            "Products" shall mean the pharmaceutical preparation or
               preparations for human use in the finished packaged form as
               described in Annex 1 attached hereto.
(ii)           "Samaritan Group" shall mean any companies directly or indirectly
               controlled by SAMARITAN under paragraph 1, n.1 of article 2359 of
               the Italian Civil Code.
(iii)          "Trademarks" shall mean the trademarks registered in the
               Territory as listed in Annex 2 attached hereto. (iv) "Marketing
               Year" shall mean a calendar year provided that the first
               Marketing Year shall run from 1
               January 2007
(v)            "Price" shall mean the price to be paid for the supply of the
               Products from MOLTENI to SAMARITAN as set forth in Annex 3
               attached hereto.
(vi)           "Territory" shall mean the Republics of Greece and Cyprus

2.             SUBJECT MATTER

2.1  MOTENI hereby grants to SAMARITAN, who hereby accepts, the exclusive right
     to import, promote, advertise, market and distribute (hereinafter, the
     "Selling Activities") the Products in the Territory, subject to the terms
     and conditions set forth in this Agreement.

2.2  In the light of the exclusive nature of the relationship set forth herein,
     for the duration of this Agreement, MOLTENI grants to SAMARITAN an
     exclusive right to use in the Territory the trademarks owned and registered
     by MOLTENI, as listed in Annex 2 attached hereto (hereinafter, the
     "Trademarks").

3.        MARKETING AUTHORIZATION

3.1     SAMARITAN and MOLTENI shall use their best effort to obtain the issuance
        of all approvals or authorizations that, pursuant to local regulatory
        authorities, may be necessary for the marketing of the Products in the
        Territory (each, a "Marketing Authorization"). In this respect, MOLTENI
        shall provide SAMARITAN with all necessary documentation (including but
        not limited to the pharmaceutical dossier of the Products).

32      SAMARITAN acknowledges that any and all rights deriving from the
        Marketing Authorization shall remain the exclusive property of MOLTENI.
        SAMARITAN acknowledges that any Marketing Authorization resulting from
        the registration process will be obtained in the name of MOLTENI and it
        will be sole proprietary of MOLTENI.

3.3     Upon request by MOLTENI, SAMARITAN shall promptly file with the
        competent authorities complete applications to obtain the required
        Marketing Authorization. All governmental costs and fees of such
        applications, if authorized in writing and in advance by MOLTENI, shall
        be borne by MOLTENI.

<PAGE>

3.4     Promptly after obtaining the Marketing Authorization, SAMARITAN shall
        provide MOLTENI with the original documentation containing the Marketing
        Authorization.

4. UNDERTAKINGS OF SAMARITAN

4.1     In addition to the other duties set out in this Agreement. SAMARITAN
        shall:
a)               purchase the Products exclusively from MOLTENI, or from those
                 persons or entities who MOLTENI may specifically authorize in
                 writing, Under no circumstances whatsoever shall SAMARITAN have
                 the right to purchase the Products from persons or entities to
                 whom MOLTENI has given no specific written authorization;
b)               market and distribute the Products exclusively in the
                 Territory. Under no circumstances whatsoever SAMARITAN shall
                 have the right to market or distribute, directly or indirectly,
                 the Products outside the Territory. SAMARITAN shall promptly
                 inform MOLTENI, in writing, of any request coming from any
                 purchaser located outside the Territory;
c)               market and distribute the Products exclusively under the
                 Trademarks.
d)               use its best reasonable commercial efforts to maximize sales in
                 the Territory and to secure the proper use and efficient
                 distribution of the Product in full adherence with all the
                 local applicable regulations.
e)               maintain at all times any required governmental, public health,
                 import permits, licenses, approvals to the extent required to
                 enable it lawfully to properly import Product and to perform
                 Selling Activities in the Territory.
f)               import and sell the Products in compliance with all applicable
                 laws and regulations in the Territory.

4.2     Furthermore, SAMARITAN shall not:
a)               manufacture, market or distribute, directly or indirectly, any
                 pharmaceutical products and/or brands that may, directly or
                 indirectly, be confused or be in competition with the Products;
                 or
b)               carry out, with respect to the Products, a sale policy
                 different from the one set out under this Agreement.
c)               be in any way, directly or indirectly, involved in or connected
                 with the marketing and/or distribution in the Territory of
                 other pharmaceutical products that either contain the same
                 active pharmaceutical ingredients or have the same dosage form
                 of the Products.
d)               assign this Agreement, in whole or in part, without the prior
                 written consent of
                 MOLTENI, provided, however that SAMARITAN may assign this
                 Agreement, in whole or in part, to any companies of the
                 Samaritan Group.

<PAGE>

5.       UNDERTAKINGS OF MOLTENI

5.1     In addition to the other duties set out in this Agreement, MOLTENI
        shall:
a)             keep SAMARITAN informed of any changes in the composition of the
               Products as well as of any other matters pertaining to the use
               and efficacy of the Products.
b)             be responsible for maintaining throughout the term of this
               Agreement all necessary marketing authorisations at the Products
               (including amendments and variations where necessary).
c)             fill in all orders for the Products in a proper and accurate way,
               pursuant to the terms and conditions set forth in this Agreement.

5.2     Furthermore, during the term of this Agreement, SAMARITAN shall not:
a)             authorize any other person to market the Products in the
               Territory; or
b)             sell or supply the Products to any person or entity which
               informed MOLTENI of its intention to sell or market the Products
               in the Territory.

6.       PURCHASE OF THE PRODUCTS

6.1     During the term of this Agreement, SAMARITAN shall provide MOLTENI, on a
        quarterly basis, with a written 18 (eighteen) month rolling forecast,
        setting forth SAMARITAN'S estimated quantities of the Products to be
        purchased by SAMARITAN during the following 18 (eighteen) months. The
        first of such forecasts shall be submitted to MOLTENI at least 5 (five)
        months before the estimated date of launch of the Products.

6.2     SAMARITAN shall provide MOLTENI with written purchase orders for the
        Products at least 90 (ninety) days before the requested delivery date.
        No order for the Products shall be binding on MOLTENI unless MOLTENI
        accepts it in writing. All purchase orders provided by SAMARITAN to
        MOLTENI shall set forth for each and all Products, among other things,
        (i) quantity, (ii) price, and (iii) requested delivery date. MOLTENI
        will use reasonable commercial endeavour to accept and fulfill orders
        for the Product placed by SAMARITAN.
6.3     Every 3 (three) months during the term of this Agreement, SAMARITAN
        shall send to MOLTENI a detailed statement of the Products sold in the
        period, by the end of the following month. This statement will show the
        different presentation of the Products sold, using the latest data
        available and/or any other market information available to SAMARITAN
        (including IMS data).

7.      MINIMUM PURCHASE TARGETS

7.1     SAMARITAN undertakes to sell Products in compliance with the Minimum
        Purchase Targets as set forth in Annex 4 attached hereto. In the event
        that at the end of each Marketing Year, SAMARITAN failed to reach the
        Minimum Purchase Targets during the immediately preceding Marketing
        Year, MOLTENI shall have the right to terminate this Agreement with
        immediate effect. In each case, SAMARITAN shall not be held liable to
        pay damages to MOLTENI in respect of such termination as it is set out
        in this article and such termination shall be MOLTENI's sole remedy in
        respect of such breach. For the purposes of this article, SAMARITAN is
        deemed to have reached the Minimum Purchase Targets where it has placed
        orders with MOLTENI, in accordance with obligations of article 6 which,
        had they been accepted by MOLTEN1 would have brought SAMARITAN above the
        relevant Minimum Purchase Targets.

<PAGE>

8.       USE OF THE TRADEMARK

8.1    MOLTENI authorizes SAMARITAN to use the Trademarks as indicated under
       Annex 3 attached hereto in the Territory for the sole purpose of
       performing its obligations as distributor of the Products under this
       Agreement and for the sole period of this Agreement.

8.2    SAMARITAN expressly acknowledges that the use of the Trademark is limited
       to the sole purpose of performing its obligations as distributor of the
       Products in the Territory under this Agreement and that such use shall
       not grant SAMARITAN any greater title or right, including the rights as
       licensee and the right to register the Trademarks under its name or for
       its own benefit. SAMARMAN acknowledges that the Trademark shall remain
       the exclusive property of MOLTENI.

8.3    Upon termination or expiration of this Agreement or on final sale of
       Product, whichever is the latest, SAMARITAN will cease all use of the
       Trademark. SAMARITAN shall not make any use or take any action with
       respect to the Trademark to prejudice or infringe MOLTENI rights thereto
       including the use of any confusingly similar trademark and shall
       forthwith, upon objection by MOLTENI, desist from any use thereof or
       action therewith which is in violation of this Agreement.

8.4    SAMARITAN shall use its best efforts to preserve the commercial
       reputation, value and prestige of the Trademark. Therefore, SAMARITAN
       shall refrain from performing any activity that may be detrimental to the
       reputation, value and prestige of the Trademark.

8.5    SAMARITAN shall promptly and fully notify MOLTENI, in writing, (,)of any
       actual or threatened infringement of the Trademark which shall come to
       its attention, and shall assist MOLTENI, at MOLTENI's request and
       expenses, in taking all necessary steps to defend the rights of MOLTENI
       in relation to such infringement. MOLTENI reserves the right to take
       whatever action it deems necessary to protect its Trademarks, reputation
       or Products against imitations, counterfeiting and unfair competition.
       Any such action to be at MOLTENI`s expense. SAMARITAN shall give all
       reasonable assistance to MOLTENI in taking action against imitations,
       counterfeiting and unfair competition by others and will give MOLTENI
       written notice of all such conduct which comes to its attention.

<PAGE>

9.       REPRESENTATIONS AND WARRANTIES OF THE PARTIES

9.1     MOLTENI warrants that the Products will conform in all respects to the
        specifications of the Products as set out in Annex 1 attached hereto
        (including, for the avoidance of doubt, its packaging) and the
        provisions of all licenses applicable to the supply of the Products
        within the Territory.

9.2     MOLTENI further warrants that the Products, on the date of supply to
        SAMARITAN, will have at least seventy percent (70%) of its shelf-life
        unelapsed, unless otherwise agreed between the Parties.

9.3     MOLTENI represents to the best of its knowledge and belief and having
        made all due enquiry that the Products will not infringe any third
        party's intellectual property rights.

9.4     SAMARITAN represents to be fully qualified to perform all acts required
        under this Agreement, and to possess the necessary organization,
        manpower, and experience to ensure an accurate distribution of the
        Products in the Territory.

10.   INDEMNIFICATION

10.1    MOLTENI shall indemnify SAMARITAN and hold it harmless from any personal
        injury claims, demands, liability, suits or expenses of any kind arising
        out of damages to or defects in the Products or in the process of
        manufacturing the Products or transport of the Products.
10.2    Where SAMARITAN receives notice of any claim from a third party claiming
        infringement of that third party's intellectual property rights,
        SAMARITAN shall promptly inform MOLTENI thereof and MOLTENI, at its sole
        discretion, shall conduct any defense of such claim or suit at its own
        expense. MOLTENI shall hold SAMARITAN harmless from and against any
        loss, claim, damage, expense or liability resulting from such claim or
        infringement with the exception of lost future profits. In any such
        action that MOLTENI will decide to undertake in the Territory, SAMARITAN
        shall assist MOLTENI in any reasonable ways without, however, assuming
        any monetary obligation.

10.3    SAMARITAN shall hold MOLTENI harmless with respect to any claims by
        other persons who allege injury or loss as a result of SAMARITAN'S (a)
        "Selling Activities" (b) use of Products, or (C) as a result of any
        other action of SAMARITAN, in each case in violation of its covenants
        under this Agreement.

10.4    SAMARITAN shall hold MOLTENI harmless from and against any claim,
        damage, injury or loss whatsoever caused and resulting from SAMARITAN's
        performance of this Agreement and any commercial activity carried out by
        SAMARITAN not in compliance with local laws and regulations. In this
        respect, SAMARITAN shall insure itself against such risks, and provide
        adequate evidence of such insurance to MOLTENI upon request.

<PAGE>

11. PROMOTION ACTIVITY

11.1    During the period of September/October preceding each Marketing Year,
        SAMARITAN shall submit to MOLTENI the Products promotion and marketing
        program prepared and proposed by SAMARITAN for the following Marketing
        Year. Any promotional material (including advertising, technical
        information, promotional materials) which SAMARITAN intends to use for
        the Selling Activities of the Products shall be submitted to MOLTENI for
        prior written approval, it being understood that such materials shall be
        deemed approved unless MOLTENI notifies SAMARITAN in writing 10 (ten)
        working days after receipt of the materials that the materials are not
        acceptable.

11.2    All costs related to the promotional material prepared and used by
        SAMARITAN for the Selling Activities of the Products will be borne by
        SAMARITAN.

12. PRICES AND PAYMENT

12.1    As consideration for the supply of the Products SAMARITAN shall pay to
        MOLTENI the Price in compliance with the terms and conditions set
        forth in Annex 4 attached hereto.
12.2    Should any material changes of production cost and/or inflation rate
        occur after the first Marketing Year such as to increase the MOLTENI's
        cost by more than ten percent (10%), the Parties agree to negotiate in
        good faith a possible modification of Price, it being understood that
        MOLTENI shall make such information available to SAMARITAN in order to
        verify that such circumstances exist.

13. STOCK OF THE PRODUCTS

        SAMARITAN shall maintain adequate stock of the Products consistent with
        the forecasted demand of Products in the Territory and the purchase
        orders delivered to MOLTENI as provided herein. SAMARITAN use only
        wholesalers who maintain or shall have maintained in a suitable and
        authorized warehouse in the Territory, properly rotated stocks of
        Products under proper storage and security conditions that comply with
        international good manufacturing practices and in sufficient quantity to
        satisfy the reasonably anticipated market requirements of at least three
        months period subject to MOLTENI having accepted and fulfilled orders.

14. NON COMPETITION

        During the term of this Agreement and for an additional one year period,
        except for termination of this agreement by MOLTENI's fault, neither
        SAMARITAN nor any companies of the Samaritan Group shall be in any way
        involved or connected with the manufacture, sale, distribution or
        promotion in the Territory, either directly or indirectly, of Products
        which consist of the same active ingredient of the Product in any
        presentation and/or formulations whatsoever.

<PAGE>

15. CLINICAL TRIALS

 15.1 SAMARITAN shall not perform clinical trials on the Products without the
prior written consent of MOLTENI.

 15.2   According to the European regulations in force, both parties shall
        report to each other promptly any information on adverse reactions
        attributable to the use of the Products following the S.O.P. hereby
        attached in Annex 5 attached hereto.

16.    TERM

16.1   This Agreement shall come into force on January 1, 2007 and shall
       remain in effect for a period of 4 (four) years. Thereafter, the
       Agreement will be automatically extended for consequent periods of 2
       (two) years each unless terminated by one of the Parties with a 6 (six)
       months prior written notice.

17 TERMINATION

 17.1   Either Party shall be entitled to terminate this Agreement at any time,
        in case the other Party materially breaches any of the terms and
        conditions of this Agreement, by giving notice of the breach to the
        Party in default. If the defaulting Party does not cure the breach
        within 30 (thirty) days after receipt of the notice, the Party who gave
        notice may terminate this Agreement upon the expiration of the 30
        (thirty) day period without prejudice to such Party's claims for damages
        or indemnification for the losses incurred by reason of such breach of
        the Agreement.

 17.2   In the event either Party becomes the subject of proceedings involving
        bankruptcy, insolvency, moratorium of payment, reorganization or
        liquidation, or if either Party makes any assignment for the benefit of
        its creditors, then this Agreement may be immediately terminated by the
        other Party by written notice, without prejudice to its claims for
        damage, reimbursement or indemnification for losses incurred in by
        reason of such termination.

17.3    Each Party shall report promptly to the other Party any major or
        significant change in its legal or beneficial ownership. If the notified
        Party reasonably believes that such change is prejudicial to its
        interests or to the proper and efficient marketing of the Products and
        the beneficial ownership of more than fifty percent (50%) of any class
        of the shares of the first party has been transferred, the notified
        Party may terminate this Agreement by giving ninety (90) days prior
        written notice within thirty (30) days after it (,)is informed of the
        change of ownership. In such instance the terminating party shall not
        owe the other for any damages or indemnification whatsoever resulting
        from the termination. Transfers of shares from existing shareholders to
        relatives or trusts for the benefit of such relatives shall not
        constitute a change in ownership and will not require notification.

<PAGE>

17.4    Under article 1456 of the Italian Civil Code, MOLTENI shall be entitled
        to terminate the Agreement at any time, by giving written notice to
        SAMARITAN, in the event that at the end of each Marketing Year,
        SAMARITAN failed to reach the Minimum Purchase Targets during the
        immediately preceding Marketing Year.

17.5 Upon expiry or termination of this Agreement, SAMARITAN shall immediately:
o        cease to refer to itself as distributor of MOLTENI;
o        cease to make any use of the Products, the samples and any promotional
         material concerning the Products;
o        cease to use in any manner  whatsoever  the Trademark as well as all
         documents  containing  the Trademark, including but not limited to
         booklets, other branded material, packaging material or labels; and
o        return to MOLTENI all the all confidential information as provided
         under the Confidentiality Agreement.

17.6  In addition to the preceding paragraph, upon expiry or termination of this
      Agreement, SAMARITAN shall immediately stop selling the Products and
      promptly deliver to MOLTENI a list of its inventory of Products. SAMARITAN
      must be able to fill orders received. Assuming that the inventory of
      Products is in sellable conditions, MOLTENI may, at its sole discretion,
      require SAMARITAN to:
o        destroy such inventory of the Products, it being understood that
         MOLTENI shall reimburse SAMARITAN for these items at the price paid
         by SAMARITAN to MOLTENI plus eventual costs related to this operation,
         or
o        deliver such inventory Product to MOLTENI or to a third party
         indicated in writing by MOLTENI, it being understood that MOLTENI
         shall reimburse SAMARITAN for these items at the price paid by
         SAMARITAN to MOLTENI plus eventual costs related to this operation,
         or
o        grant to SAMARITAN a reasonable period of time for selling the
         remaining inventory of Products, and SAMARITAN shall promptly react
         accordingly.

18     FORCE MAJEURE

        Neither Party to this Agreement shall be liable for failure to perform
        if the failure is attributable to any cause which is reasonably beyond
        the party's control, including:

(a)         war (declared or undeclared), riot, political insurrection,
            rebellion, revolution, terroristic acts;
(b)         acts or orders of or expropriation by any government (whether de
            facto or de jure) prohibiting the import or export of the goods
            covered hereby imposing or rationing;
(c)         inability to procure or shortage of supplies of necessary materials,
            equipment, or Production facilities;
(d)         quarantine restrictions;

<PAGE>

(e)         fuel shortage;
(f)         strike lockout, or other labour troubles which interfere with the
            manufacture, sale or transportation of the goods covered hereby or
            with the supply of raw materials necessary for their Production;
(g)         fire, flood, explosion, earthquake, tornadoes or other natural
            events.

19.         NOTICES

Any notice or communication to be given or any request to be made by either
Party to the other pursuant to the provisions of this Agreement shall be given
by sending such notice via registered mail to the following addresses, or to
such other addresses each Party may have designated to the to the other in
writing:

              a) As to MOLTENI:
              Address: Localita Granatieri Scandicci Firenze Italy
              Phone number: +39 055 7361226
              Fax number: +39 055 7361257
              To the kind attention of: Francesco Summo

              b) As to SAMARITAN
              Address: 41 Skoufa Street, Athens-106 73 Phone number: + 30 210
              3392060
              Fax number: +30 210 3392062
              To the kind attention of: Dr. Christos Dakas

20.      MISCELLANEOUS

20.1    The relationship between the Parties is that of independent contractors
        and each Party agrees to conduct its affairs accordingly. Nothing in
        this Agreement or in the activities engaged in by MOLTENI or SAMARITAN
        hereunder shall create an agency, partnership, employment or joint
        venture relationship between the Parties.

20.2    English shall be the official version of the Agreement for the purpose
        of interpretation,

20.3    The failure of either Party in any one or more instances to insist upon
        strict performance of any of the terms and conditions of this Agreement
        shall not be construed as a waiver or relinquishment, to any extent, of
        the right to assert or rely upon any such terms or conditions on any
        future occasion.

20.4    This Agreement constitutes the definitive agreement of the Parties on
        the subject matter hereof and supersedes, cancels and annuls all prior
        agreements, understandings and undertakings relating to the subject
        matter hereof. This Agreement shall not be modified or amended except by
        a written document signed by a duly authorized officer of the parties.
        There are no verbal agreements, warranties, representations or
        understandings affecting this Agreement and all previous or other
        negotiations, representations, and understandings between the parties
        are merges herein.

<PAGE>

 20.5   If any provision of this Agreement is found by any court or
        administrative body of competent jurisdiction to be invalid or
        unenforceable, the invalidity or unenforceability of such provision
        shall not effect the other provisions of this Agreement, and all
        provisions not effected by such invalidity or unenforceability shall
        remain in full force and effect. The Parties agree to attempt to
        substitute for any invalid or unenforceable provision a valid or
        enforceable provision which achieves to the greatest extent possible
        economic objectives of the invalid or unenforceable provision.
20.6    This Agreement shall be governed by and construed in accordance with the
        laws of Italy.
20.7    The Court of Milan shall have exclusive jurisdiction over any dispute
        arising out from or in connection with this Agreement.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
in 2 (two) original copies by their duly authorized representatives, on the date
written below.

L. MOLTENI & C. dei F .lli Alitti Societa di Esercizio S.p.A. Samaritan
Pharmaceutical Europe SA Esercizio S.p.A.

By: /s/ Federico Seghi-Recli,                         By: /s/ Christos Dakas
Managing Director                                     Managing Director
-----------------------------                         --------------------------
Federico Seghi-Recli                                  Christos Dakas

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]